Navigation Links
Avantra Biosciences and MedTrust Online Partner to Develop Clinically Important Protein Biomarker Assays for Improving Cancer Care
Date:2/22/2011

WOBURN, Mass., Feb. 22, 2011 /PRNewswire/ -- MedTrust Online (MedTrust) and Avantra Biosciences (Avantra) announced today a novel collaboration to involve clinicians in the earliest stages of molecular diagnostic assay development for Avantra Biosciences' revolutionary QPDx™ multiplex immunoassay system.

The two companies will provide a global community of over 10,000 cancer care professionals with early access to the latest panels of protein biomarkers implicated in different cancers.  Avantra, based in Woburn, MA, is a leading innovator in protein diagnostics and recently announced the commercialization of the new Q400 Biomarker Workstation and innovative AngioGenQx™ BioChip immunoassay.  The system provides quantitative protein biomarker results for ten analytes in less than an hour, requiring only five minutes for sample preparation.  

As Avantra's scientific development team identifies biomarkers of interest for its QPDx™ system, MedTrust will use its Knowledge Medicine™ platform to engage oncologists in online discussions that will validate the role of different panels in diagnosis, prognosis, and treatment efficacy in cancer care.  The first of several multiplex assays to be evaluated include an upcoming panel developed in the recently announced collaboration between Avantra and TGen Drug Development.  Avantra intends to develop additional panels that may target ovarian, pancreatic, lung, prostate, breast, and colorectal cancers to uncover associations between protein marker levels and patient drug responses that can positively impact clinical decisions.   Currently available for research use only (RUO), Avantra intends to seek regulatory approval for its assay technologies as the clinical utility of the molecular information becomes evident.   In addition to oncology, Avantra is exploring opportunities in other areas such as infectious disease through its upcoming panel for sepsis.
'/>"/>

SOURCE Avantra Biosciences Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Avantra Biosciences Launches Multiplex System for Faster, Easier Quantification of Cancer Protein Biomarkers
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015  Impax Laboratories, Inc. (NASDAQ: IPXL ) ... roles, appointing  Donna M. Hughes, as Senior Vice President, ... Senior Vice President, Chief Compliance Officer. Both Ms. Hughes ... Chief Executive Officer, Fred Wilkinson . ... the Impax team," said Fred Wilkinson , President ...
(Date:5/4/2015)... N.J. , May 4, 2015  Oncobiologics, ... commercializing monoclonal antibody (mAb) biosimilars, has completed the ... at its headquarters in Cranbury, New ... Cranbury facility is designed to utilize ... manufacturing at commercial scale.  Through the use of ...
(Date:5/4/2015)... N.Y. , May 4, 2015  Clinical ... Englert , PharmD, has completed preliminary analysis of ... and Schizophrenia. Resources from Clinical Support Services, Inc. ... Reviews (CMR) with patients currently taking psychiatric medications ... The research found that 93% of patients experienced ...
Breaking Medicine Technology:Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3
... Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced ... NBI-98854 in 37 tardive dyskinesia patients. For the final analysis, ... and incorrect application of the efficacy assessment protocol. With this ... dyskinesia symptoms at end of two weeks of active treatment ...
... treatment may target hunger at its source, another uses ... stomach and suppress hunger and a third explores the ... Initial results from all these studies were reported at ... in San Francisco, Calif. (Logo: ...
Cached Medicine Technology:Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 2Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 3Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 4Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 5Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 6Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 7No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 2No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 3No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 4No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 5No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 6
(Date:5/4/2015)... (PRWEB) May 04, 2015 Takeda Pharmaceuticals ... billion to settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ... increases the risk that a patient will develop bladder ... 28th, if 95% of those eligible for the Actos ... 9,000 bladder cancer cases currently pending in courts around ...
(Date:5/4/2015)... NY (PRWEB) May 04, 2015 ... insurance programs, announces the expansion of coverage for its ... a leading provider of industry-tailored insurance and proactive risk ... & Company, we are dedicated to providing our customers ... meet their many evolving needs. We are excited to ...
(Date:5/4/2015)... PROVIDENCE, R.I. (PRWEB) May 04, 2015 Johnson ... new $40 million engineering and science academic center on Wednesday, ... in the ground for land made available by the re-alignment ... at the corner of Friendship and Chestnut streets in Providence, ... being built on a parcel of land the university purchased ...
(Date:5/4/2015)... 04, 2015 TROY Healthcare Solutions is ... Atlantic Regional User Group (RUG) Conference in Baltimore, MD ... Atlantic Regional User Group provides an opportunity for clients ... the exhibitor gallery. , In addition to sponsoring the ... Cerner North Atlantic RUG Conference. Attendees can stop by ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 The American ... critical state policy reports which identify gaps in coverage ... “After ATA issued the State Telemedicine Gaps Reports last ... how their laws and regulations impact healthcare delivery in ... a result of state actions across the nation, ATA ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3
... The American Academy of Cosmetic Surgery (AACS) 2006 Consumer Perspective ... US citizens have had cosmetic surgery//, a great number are ... ,Jeff Knezovich, executive vice president of the American Academy ... lot since the 1970s when such surgery was rarely mentioned. ...
... 200 children were taken ill after eating lunch at their ... were admitted to a hospital and are reportedly in a ... Dianshi Town High School began reporting symptoms of headache, stomach ... Monday and were immediately hopitalised. ,The food samples ...
... Health and Family Welfare Minister Anbumani Ramadoss today officially ... The highly contagious disease was prevalent among tribals living ... Last year it was leprosy and this year it ... that India had moved closer to completely eliminating yaws ...
... Children are being exposed to the risk of liver damage ... lead and cadmium found in plastic and other soft toys ... ,"Dangerous levels of lead and cadmium have been found ... the markets," said Toxics Link, an environmental non-governmental organisation, in ...
... that caused by hay fever and other allergies, have ... without allergies, according to a report in the September ... issue on sleep. ,Allergic rhinitis, which occurs ... nasal passages, affects about 20 to 50 percent of ...
... bottles of Similac Infant Formula were off the shelf, after ... following a suspected flaw in the bottle. No repercussions after ... the company has decided to recall the product in order ... C content in the bottle. ,Given ...
Cached Medicine News:Health News:Dangers Lurking in Soft, Cuddly Toys 2Health News:Allergic Rhinitis Associated with Impaired Sleep Quality 2
... has a complete offering of cardiology catheters. ... these catheters are designed with excellent torque, ... and better push-ability, and large inner lumens ... 5, 6 and 7 French sizes with ...
Used to negotiate tortuous vessels....
Used for vascular and non-vascular applications. Tapered fixed core construction provides gradual transition to a flexible,tip. Supplied sterile in peel-open packages. Intended for one-time use....
Used to negotiate tortuous vessels....
Medicine Products: